-
Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock
-
Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock
-
Turning Point Therapeutics Inc. (TPTX) Announces Commencement of $400M Public Offering of Common Stock
-
Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock
-
Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock
-
Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference
-
Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference
-
Turning Point Therapeutics Inc. (TPTX) PT Raised to $77 at Roth Capital, Following Drug Trial Data Release
-
Roth Capital Starts Turning Point Therapeutics Inc. (TPTX) at Buy

